论文部分内容阅读
目的:探讨在宫颈癌检查中使用高危型HPVDNA检测的临床价值。方法:选取2015年4~2016年5月到我院接受常规妇科检查的妇女542例为研究对象,对患者做TCT与高危型HPVDNA检测。结果:高危型HPVDNA检测敏感率为90.41%,而TCT检测敏感率为48.15%,可见HPVDNA检测与TCT相比,对宫颈炎症以上病变检测敏感率大幅提高,差异有统计学意义(P<0.05)。良性病变或者慢性炎症、局部湿疣或尖锐湿疣的HPVDNA载量较低,其中LSIL、HSIL的HPVDNA载量明显比良性病变或者慢性炎症要高,差异有统计学意义(P<0.05)。结论:采用高危型HPVDNA检测在早期宫颈癌筛选上具有非常高的敏感性,能够减少癌症的漏诊,这对宫颈癌的早期诊断与治疗提供帮助。
Objective: To investigate the clinical value of using high-risk HPVDNA in cervical cancer screening. Methods: 542 women admitted to our hospital for routine gynecological examinations from April 2015 to May 2016 were selected as the study subjects, and TCT and high-risk HPV DNA were detected in the patients. Results: The sensitive rate of high-risk HPV DNA detection was 90.41%, while the sensitivity of TCT detection was 48.15%. Compared with TCT, HPVDNA detection rate of cervical lesions increased significantly, the difference was statistically significant (P <0.05) . The HPVDNA load of benign or chronic inflammation, genital warts or condyloma acuminatum was lower, and the HPVDNA load of LSIL and HSIL was significantly higher than benign or chronic inflammation (P <0.05). Conclusion: The high-risk HPV DNA test has a very high sensitivity in screening early cervical cancer and can reduce the missed diagnosis of cancer, which can help to diagnose and treat cervical cancer early.